688293 奥浦迈
交易中 12-16 14:07:56
资讯
新帖
简况
奥浦迈（688293）披露关于公司独立董事离任的公告，12月15日股价下跌0.41%
证券之星 · 12-15 17:59
奥浦迈（688293）披露关于公司独立董事离任的公告，12月15日股价下跌0.41%
借政策东风补链强链 奥浦迈14.51亿元收购澎立生物
证券日报 · 12-10
借政策东风补链强链 奥浦迈14.51亿元收购澎立生物
奥浦迈并购澎立生物相关事项过会
市场资讯 · 12-08
奥浦迈并购澎立生物相关事项过会
12月2日奥浦迈跌8.01%，招商医药健康产业股票基金重仓该股
证券之星 · 12-02
12月2日奥浦迈跌8.01%，招商医药健康产业股票基金重仓该股
每周股票复盘：奥浦迈（688293）重组进展至二次修订稿披露
证券之星 · 11-23
每周股票复盘：奥浦迈（688293）重组进展至二次修订稿披露
奥浦迈（688293）披露拟变更注册资本及取消监事会，11月20日股价上涨2.22%
证券之星 · 11-20
奥浦迈（688293）披露拟变更注册资本及取消监事会，11月20日股价上涨2.22%
奥浦迈：广发基金、平安医药等多家机构于11月14日调研我司
证券之星 · 11-18
奥浦迈：广发基金、平安医药等多家机构于11月14日调研我司
每周股票复盘：奥浦迈（688293）Q3营收增25.79%，拟购澎立生物100%股权
证券之星 · 11-16
每周股票复盘：奥浦迈（688293）Q3营收增25.79%，拟购澎立生物100%股权
奥浦迈（688293）披露变更注册资本及修订公司章程公告，11月14日股价上涨0.34%
中金财经 · 11-15
奥浦迈（688293）披露变更注册资本及修订公司章程公告，11月14日股价上涨0.34%
奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？
新浪证券 · 11-13
奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？
奥浦迈生物董事长肖志华：在国际化方面要走出独特的道路，稳扎稳打以质量与创新取胜
新浪证券 · 11-13
奥浦迈生物董事长肖志华：在国际化方面要走出独特的道路，稳扎稳打以质量与创新取胜
股市必读：新发布《奥浦迈：关于发行股份及支付现金购买资产并募集配套资金审核问询函回复（修订稿）的提示性公告》
证券之星 · 11-12
股市必读：新发布《奥浦迈：关于发行股份及支付现金购买资产并募集配套资金审核问询函回复（修订稿）的提示性公告》
独董再投反对票！奥浦迈并购澎立生物背后的疑问
市场资讯 · 11-11
独董再投反对票！奥浦迈并购澎立生物背后的疑问
11月10日奥浦迈涨9.68%，招商医药健康产业股票基金重仓该股
证券之星 · 11-10
11月10日奥浦迈涨9.68%，招商医药健康产业股票基金重仓该股
奥浦迈涨9.68%，开源证券二个月前给出“买入”评级
证券之星 · 11-10
奥浦迈涨9.68%，开源证券二个月前给出“买入”评级
每周股票复盘：奥浦迈（688293）Q3净利同比增283.59%
证券之星 · 11-02
每周股票复盘：奥浦迈（688293）Q3净利同比增283.59%
图解奥浦迈三季报：第三季度单季净利润同比增长283.59%
证券之星 · 10-29
图解奥浦迈三季报：第三季度单季净利润同比增长283.59%
奥浦迈(688293)9月30日股东户数0.37万户，较上期增加14.63%
证券之星 · 10-29
奥浦迈(688293)9月30日股东户数0.37万户，较上期增加14.63%
每周股票复盘：奥浦迈（688293）限制性股票归属27.14万股
证券之星 · 10-19
每周股票复盘：奥浦迈（688293）限制性股票归属27.14万股
奥浦迈（688293）披露2023年限制性股票激励计划归属结果暨股份上市公告，10月17日股价下跌3.63%
证券之星 · 10-17
奥浦迈（688293）披露2023年限制性股票激励计划归属结果暨股份上市公告，10月17日股价下跌3.63%
加载更多
公司概况
公司名称：
上海奥浦迈生物科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-09-02
主营业务：
上海奥浦迈生物科技股份有限公司的主营业务是细胞培养产品与服务。公司的主要产品是高品质培养基、抗体药物开发CDMO服务平台。
发行价格：
80.20
{"stockData":{"symbol":"688293","market":"SH","secType":"STK","nameCN":"奥浦迈","latestPrice":52.45,"timestamp":1765865276000,"preClose":53.13,"halted":0,"volume":281729,"delay":0,"changeRate":-0.0128,"floatShares":113999999,"shares":113999999,"eps":0.38,"marketStatus":"交易中","change":-0.68,"latestTime":"12-16 14:07:56","open":53.02,"high":53.51,"low":52.14,"amount":14877000,"amplitude":0.0258,"askPrice":52.45,"askSize":4,"bidPrice":52.37,"bidSize":19,"shortable":0,"etf":0,"ttmEps":0.38,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765868400000},"marketStatusCode":2,"adr":0,"adjPreClose":53.13,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765848600000,1765855800000],[1765861200000,1765868400000]],"highLimit":58.44,"lowLimit":47.82,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":113820154,"isCdr":false,"pbRate":2.88,"roa":"--","peRate":138.026316,"roe":"2.34%","epsLYR":0.19,"committee":-0.097561,"marketValue":5970000000,"turnoverRate":0.0025,"status":1,"floatMarketCap":5970000000},"requestUrl":"/m/hq/s/688293","defaultTab":"news","newsList":[{"id":"2591461798","title":"奥浦迈（688293）披露关于公司独立董事离任的公告，12月15日股价下跌0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591461798","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591461798?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:59","pubTimestamp":1765792771,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，奥浦迈报收于53.13元，较前一交易日下跌0.41%，最新总市值为60.47亿元。其离任将导致公司独立董事人数低于法定比例，在新任独立董事选举产生前，陶化安将继续履职。公司董事会对陶化安在任职期间的贡献表示感谢。截至公告日，陶化安未持有公司股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500023567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2590385595","title":"借政策东风补链强链 奥浦迈14.51亿元收购澎立生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2590385595","media":"证券日报 ","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590385595?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:42","pubTimestamp":1765374120,"startTime":"0","endTime":"0","summary":"2025年前三季度，奥浦迈的细胞培养产品业务实现营业收入2.39亿元，同比增长32.56%，是该公司营业收入的“核心支柱”；同期，该公司CDMO服务业务实现营业收入为3258万元，同比略有下降。 奥浦迈拟并购标的为澎立生物。2025年上半年，澎立生物的营业收入为1.87亿元，归属于母公司所有者的净利润为2386万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-10/doc-inhaiqia8721285.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-10/doc-inhaiqia8721285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2590361200","title":"奥浦迈并购澎立生物相关事项过会","url":"https://stock-news.laohu8.com/highlight/detail?id=2590361200","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590361200?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:40","pubTimestamp":1765201200,"startTime":"0","endTime":"0","summary":" 据了解，奥浦迈拟通过发行股份及支付现金方式购买澎立生物医药技术（上海）股份有限公司100%股权，并向不超过35名特定投资者发行股票募集配套资金。 在重组委会议上，上交所重组委要求奥浦迈结合公司和澎立生物业务布局、目前主要收入覆盖疾病领域、境内外收入结构差异等，说明协同效应的实现方式以及风险揭示的充分性。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-08/doc-inhacaaw3436013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2588080530","title":"12月2日奥浦迈跌8.01%，招商医药健康产业股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588080530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588080530?lang=zh_cn&edition=full","pubTime":"2025-12-02 15:32","pubTimestamp":1764660758,"startTime":"0","endTime":"0","summary":"证券之星消息，12月2日奥浦迈跌8.01%，收盘报50.32元，换手率2.93%，成交量3.34万手，成交额1.71亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为招商基金的招商医药健康产业股票。该公募基金现任基金经理为李佳存。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200017309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2585050551","title":"每周股票复盘：奥浦迈（688293）重组进展至二次修订稿披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2585050551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585050551?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:11","pubTimestamp":1763842274,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，奥浦迈报收于54.81元，较上周的58.7元下跌6.63%。本周，奥浦迈11月19日盘中最高价报59.89元。本周关注点来自机构调研要点：公司重组报告书已披露二次修订稿，目前处于审核阶段。来自公司公告汇总：公司拟取消监事会，由董事会审计委员会行使其职权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2584158303","title":"奥浦迈（688293）披露拟变更注册资本及取消监事会，11月20日股价上涨2.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584158303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584158303?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:39","pubTimestamp":1763649560,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘，奥浦迈报收于58.95元，较前一交易日上涨2.22%，最新总市值为67.1亿元。该股当日开盘57.8元，最高59.68元，最低56.81元，成交额达7170.35万元，换手率为1.07%。公司近日发布公告，披露了《2025年第三次临时股东大会会议资料》。公告显示，因限制性股票激励计划归属完成，奥浦迈拟变更公司注册资本，总股本由113,548,754股增至113,820,154股，注册资本相应增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2584609731","title":"奥浦迈：广发基金、平安医药等多家机构于11月14日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2584609731","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584609731?lang=zh_cn&edition=full","pubTime":"2025-11-18 09:32","pubTimestamp":1763429547,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年11月17日奥浦迈发布公告称广发基金周飞、平安医药倪亦道、兴业证券乔波耀 黄翰漾、海月资本杨雨晨、东吴自营于彦秋、易方达陈峻松于2025年11月14日调研我司。截至第三季度末,国内共有311个已确定中试工艺的药品研发管线使用公司的细胞培养基产品,整体相较2024年末增加64个,其中商业化生产阶段增至13个。2024年,公司建成了美国研发实验室并于今年投入使用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800007409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","09939","688293","159938","BK0216","BK1515"],"gpt_icon":0},{"id":"2583516626","title":"每周股票复盘：奥浦迈（688293）Q3营收增25.79%，拟购澎立生物100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2583516626","media":"证券之星","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583516626?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:27","pubTimestamp":1763234832,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，奥浦迈报收于58.7元，较上周的56.0元上涨4.82%。交易对方共31名，其中51.05%对价以发行股份支付，48.95%以现金支付。股本股东变化因限制性股票激励计划股份归属，公司总股本由113,548,754股增至113,820,154股，注册资本相应增加。公司2025年前三季度实现营业收入27,152.72万元,同比增长25.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293"],"gpt_icon":0},{"id":"2583902633","title":"奥浦迈（688293）披露变更注册资本及修订公司章程公告，11月14日股价上涨0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583902633","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583902633?lang=zh_cn&edition=full","pubTime":"2025-11-15 08:40","pubTimestamp":1763167241,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，将于2025年12月1日召开2025年第三次临时股东大会，会议将采取现场投票与网络投票相结合的方式进行。会议主要审议《关于变更注册资本、取消监事会、修订<公司章程>并办理工商变更登记的议案》以及多项公司治理制度修订议案。股东需于2025年11月24日前完成登记，并提供身份及持股证明材料。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251115/31798104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2583562646","title":"奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562646","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583562646?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:07","pubTimestamp":1763035620,"startTime":"0","endTime":"0","summary":" 11月13日，在上海证券交易所国际投资者大会的圆桌论坛上，嘉宾们围绕“中国能否诞生世界级的医药企业？” 杭州奥泰生物技术股份有限公司董事长、总经理高飞表示，世界级企业在中国“肯定会出现”。他表示，生物医药企业要在全球产生价值，必须先在中国市场形成价值基础，而国家在政策端的持续支持至关重要。 现场讨论认为，随着创新能力提升、政策不断完善，中国医药产业未来有望孕育世界级的一流企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-13/doc-infxhkcu5227361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","LU2488822045.USD","LU1064130708.USD","LU2097828557.USD","LU1820825898.SGD","LU2148510915.USD","LU1997245177.USD","LU1969619763.USD","LU1781817850.SGD","LU0405327148.USD","688606","LU0405327494.USD","LU2580892862.HKD","BK0196","BK0239","LU1997245094.SGD","01276","LU1997244956.HKD","LU2289578879.USD","600276","LU0359201885.HKD","LU1146622755.USD","LU1255011170.USD","BK0028","LU2580892789.USD","BK0012","LU2097828474.EUR","LU0359201612.USD","LU2097828631.EUR","LU2328871848.SGD","LU2097828805.USD","BK0188","LU1064131003.USD","BK0060","LU2097828714.EUR","LU2543165471.USD","688293","LU1023057109.AUD","LU1655091616.SGD","LU2495084118.USD","LU1328615791.USD","LU1580142542.USD","BK0216","LU0359202008.SGD","BK0183"],"gpt_icon":0},{"id":"2583367045","title":"奥浦迈生物董事长肖志华：在国际化方面要走出独特的道路，稳扎稳打以质量与创新取胜","url":"https://stock-news.laohu8.com/highlight/detail?id=2583367045","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583367045?lang=zh_cn&edition=full","pubTime":"2025-11-13 11:01","pubTimestamp":1763002860,"startTime":"0","endTime":"0","summary":" 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 文/新浪财经上海站 陈秀颖。 11月13日，在上海证券交易所国际投资者大会的圆桌论坛上，上海奥浦迈生物科技股份有限公司董事长肖志华围绕“中国能否诞生世界级的医药企业”发表了精彩观点。 肖志华指出，成为全球化企业的关键在于坚守核心业务、推动并购整合与资本驱动的协同发展。“要走出独特的道路，稳扎稳打，以质量与创新取胜。”","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-11-13/doc-infxfnye5571497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2582391173","title":"股市必读：新发布《奥浦迈：关于发行股份及支付现金购买资产并募集配套资金审核问询函回复（修订稿）的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2582391173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582391173?lang=zh_cn&edition=full","pubTime":"2025-11-12 03:01","pubTimestamp":1762887677,"startTime":"0","endTime":"0","summary":"国泰海通证券股份有限公司关于上海奥浦迈生物科技股份有限公司发行股份及支付现金购买资产并募集配套资金之独立财务顾问报告（修订稿）国泰海通证券作为独立财务顾问，对上海奥浦迈生物科技股份有限公司发行股份及支付现金购买资产并募集配套资金事项出具独立财务顾问报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200001374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2582369576","title":"独董再投反对票！奥浦迈并购澎立生物背后的疑问","url":"https://stock-news.laohu8.com/highlight/detail?id=2582369576","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582369576?lang=zh_cn&edition=full","pubTime":"2025-11-11 20:08","pubTimestamp":1762862880,"startTime":"0","endTime":"0","summary":" 奥浦迈重组事项迎来新进展。11月11日，奥浦迈披露了收购澎立生物医药技术（上海）股份有限公司100%股权草案的二次修订稿，这笔总额高达14.51亿元的并购案步入新阶段。同时，澎立生物的业绩呈现下滑态势。值得一提的是，独立董事陶化安再次对这一并购议案投下反对票，其认为公司现阶段不具有并购的必要性。 重组草案显示，奥浦迈拟以发行股份及支付现金的方式向31名交易对方购买澎立生物100%的股权，并募集配套资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-11-11/doc-infwzvxw7134576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2582237428","title":"11月10日奥浦迈涨9.68%，招商医药健康产业股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582237428","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582237428?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:29","pubTimestamp":1762763374,"startTime":"0","endTime":"0","summary":"证券之星消息，11月10日奥浦迈涨9.68%，收盘报61.42元，换手率2.37%，成交量2.7万手，成交额1.61亿元。重仓奥浦迈的前十大公募基金请见下表：该股最近90天内共有7家机构给出评级，买入评级5家，增持评级2家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为招商基金的招商医药健康产业股票。该公募基金现任基金经理为李佳存。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000020637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2582823039","title":"奥浦迈涨9.68%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2582823039","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582823039?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:29","pubTimestamp":1762763366,"startTime":"0","endTime":"0","summary":"今日奥浦迈涨9.68%，收盘报61.42元。2025年8月27日，开源证券研究员余汝意,聂媛媛发布了对奥浦迈的研报《公司信息更新报告：海外培养基业务维持高增长，公司盈利能力持续提升》，该研报对奥浦迈给出“买入”评级。研报中预计公司2025-2027年归母净利润分别为0.75/1.02/1.33亿元，EPS为0.66/0.90/1.18元，当前股价对应P/E分别为85.9/62.9/48.0倍，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为开源证券的聂媛媛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000020634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","161027"],"gpt_icon":0},{"id":"2580794704","title":"每周股票复盘：奥浦迈（688293）Q3净利同比增283.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580794704","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580794704?lang=zh_cn&edition=full","pubTime":"2025-11-02 04:34","pubTimestamp":1762029252,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，奥浦迈报收于61.88元，较上周的56.48元上涨9.56%。股本股东变化截至2025年9月30日，奥浦迈股东户数为3682.0户，较6月30日增加470.0户，增幅14.63%。业绩披露要点奥浦迈2025年三季报显示，前三季度主营收入2.72亿元，同比上升25.79%；归母净利润4942.53万元，同比上升81.48%；扣非净利润3736.92万元，同比上升118.8%。2025年第三季度单季度主营收入9377.91万元，同比上升29.8%；单季度归母净利润1187.84万元，同比上升283.59%；单季度扣非净利润779.18万元，同比上升2174.87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2579974680","title":"图解奥浦迈三季报：第三季度单季净利润同比增长283.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579974680","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579974680?lang=zh_cn&edition=full","pubTime":"2025-10-29 18:58","pubTimestamp":1761735517,"startTime":"0","endTime":"0","summary":"证券之星消息，奥浦迈2025年三季报显示，前三季度公司主营收入2.72亿元，同比上升25.79%；归母净利润4942.53万元，同比上升81.48%；扣非净利润3736.92万元，同比上升118.8%；其中2025年第三季度，公司单季度主营收入9377.91万元，同比上升29.8%；单季度归母净利润1187.84万元，同比上升283.59%；单季度扣非净利润779.18万元，同比上升2174.87%；负债率7.59%，投资收益1998.61万元，财务费用-1352.73万元，毛利率54.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900039679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293"],"gpt_icon":0},{"id":"2579202479","title":"奥浦迈(688293)9月30日股东户数0.37万户，较上期增加14.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579202479","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579202479?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:22","pubTimestamp":1761729738,"startTime":"0","endTime":"0","summary":"证券之星消息，近日奥浦迈披露，截至2025年9月30日公司股东户数为3682.0户，较6月30日增加470.0户，增幅为14.63%。在生物制品行业个股中，奥浦迈股东户数低于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.4万户。从股价来看，2025年6月30日至2025年9月30日，奥浦迈区间涨幅为43.31%，在此期间股东户数增加470.0户，增幅为14.63%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900035657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2576204118","title":"每周股票复盘：奥浦迈（688293）限制性股票归属27.14万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2576204118","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576204118?lang=zh_cn&edition=full","pubTime":"2025-10-19 04:24","pubTimestamp":1760819050,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，奥浦迈报收于55.17元，较上周的61.0元下跌9.56%。本周关注点公司公告汇总：奥浦迈完成限制性股票激励计划部分归属，新增流通股271,400股。本次归属后总股本增至113,820,154股，实际控制人未发生变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2576051619","title":"奥浦迈（688293）披露2023年限制性股票激励计划归属结果暨股份上市公告，10月17日股价下跌3.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576051619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576051619?lang=zh_cn&edition=full","pubTime":"2025-10-17 22:43","pubTimestamp":1760712191,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，奥浦迈报收于55.17元，较前一交易日下跌3.63%，最新总市值为62.64亿元。近日，奥浦迈发布关于2023年限制性股票激励计划首次授予部分第二个归属期、预留授予部分第一个归属期第一次归属结果暨股份上市的公告。股份登记已于2025年10月16日完成，立信会计师事务所已对出资情况进行验资。本次归属后公司总股本增至113,820,154股，实际控制人未发生变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700038706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765865287263,"stockEarnings":[{"period":"1week","weight":0.0295},{"period":"1month","weight":-0.0949},{"period":"3month","weight":-0.009},{"period":"6month","weight":0.4341},{"period":"1year","weight":0.285},{"period":"ytd","weight":0.47}],"compareEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":-0.0307},{"period":"3month","weight":0.0016},{"period":"6month","weight":0.1414},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.154}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海奥浦迈生物科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"3682人(较上一季度增加14.63%)","perCapita":"30912股","listingDate":"2022-09-02","address":"上海市浦东新区紫萍路908弄28号","registeredCapital":"11382万元","survey":" 上海奥浦迈生物科技股份有限公司的主营业务是细胞培养产品与服务。公司的主要产品是高品质培养基、抗体药物开发CDMO服务平台。","listedPrice":80.2},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥浦迈(688293)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥浦迈(688293)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥浦迈,688293,奥浦迈股票,奥浦迈股票老虎,奥浦迈股票老虎国际,奥浦迈行情,奥浦迈股票行情,奥浦迈股价,奥浦迈股市,奥浦迈股票价格,奥浦迈股票交易,奥浦迈股票购买,奥浦迈股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥浦迈(688293)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥浦迈(688293)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}